48results about How to "Reduce hypertrophy" patented technology

Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin are disclosed. In particular, the invention relates to formulations comprising apelin encapsulated in liposome nanocarriers conjugated with polyethylene glycol (PEG) and their use in treatment of cardiovascular and pulmonary diseases and disorders. Encapsulation of apelin in PEG-conjugated liposomes significantly enhances efficacy, improves cellular uptake of apelin, and allows for sustained and extended release of apelin under physiological conditions.

The invention provides a biodegradable cardia support. The biodegradable cardia support comprises a biodegradable support framework which is formed by weave of biodegradable high polymer material filaments, and a layer of controlled-release drug layer is coated on the surface of the biodegradable support framework. The support framework and drug carriers are made of high polymer biodegradable materials and can fully and automatically degradate after time window treatment is finished, and therefore the trouble of taking out the support is avoided. In addition, the controlled-release drug layer can release anti-inflammatory drugs stably through drug controlled-release technology, and therefore fibroblast hyperplasia caused by esophagus repair reaction can be effectively restrained, subsequent scar tissue hyperplasia and thickening can be reduced, and tissue hyperplasia on the surface of the support after the support is implanted is restrained. Thus, the time window of support implantation treatment can be prolonged, supporting force of the support on tube walls can be increased, and long-dated reappearance can be reduced.

A method is provided for reducing hypertension and/or heart failure in a mammal. Preferably, the method is used to treat or prevent tissue damage to a human heart. The method includes administering an effective amount of a Jak2 inhibitor, preferably a tyrphostin, such as AG490.

The invention provides a tablet for assisting to reduce blood glucose and a preparation method. The tablet for assisting to reduce blood glucose comprises the following main raw materials in parts by weight: 100-130 parts of folium mori extract, 100-130 parts of bitter gourd extract, 30-60 parts of American ginseng extract, 50-100 parts of pseudo-ginseng extract, 50-100 parts of lucid ganoderma extract, 50-100 parts of astragalus membranaceus extract, and 8-15 parts of chromium-enriched yeast. The tablet for assisting to reduce blood glucose further comprises the following auxiliary materials in parts by weight: 150-200 parts of dextrin, 5-10 parts of magnesium stearate, and 10-15 parts of coating powder. According to the invention, the blood glucose of a diabetic patient is reduced by utilizing the complementarily synergistic effect of various components; and the tablet disclosed by the invention is also capable of reducing blood pressure, blood fat and blood viscosity, improving microcirculation to prevent peripheral neuropathy, improving ischemic and anaerobic states of brains and various tissues, increasing organism antioxygen ability, improving retinopathy, and increasing organism immunity.

The invention discloses application of a glutaminase inhibitor in preparation of a medicine for treating psoriasis. In-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, including remarkably reducing the Baker score of skin lesion, effectively reducing the epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing the medicine for treating psoriasis.

The compound fertilizer composed of (wt%) N 10-13, P 3-15, K 5-20, Ca 3-15, Mg 1-8, B 0-1, they are grinded, mixed, prilled, dried, cooled and screened to produce the compound fertilizer. the raw material used by this compound fertilizer is agricultural fertilizer sold in market, the compound fertilizer can provides ntrition required by loquat growing, blooming and fruiting.

The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents.

The present invention belongs to the technical field of food and particularly relates to nutrition powder for prostate, and a preparation method and an application thereof. The nutrition powder for the prostate comprises the following components in parts by weight: 5-15 parts of tomatoes, 30-60 parts of Chinese chestnuts, 3-7 parts of coix seeds, 3-7 parts of fructus rubi, 3-7 parts of Chinese wolfberry fruits, 3-7 parts of apples, 5-15 parts of Chinese yams, and 3-7 parts of wax gourd kernels. Test results show that the nutrition powder for the prostate has a preventive and therapeutic effect on experimental bacterial and non-bacterial acute and chronic prostatitis.

The invention discloses a herba taxilli tea granule composition, which is prepared from the following ingredients: 80 to 200 parts of herba taxilli extracts and 60 to 150 parts of radix astragali extracts. The invention aims at providing the herba taxilli tea granule composition has the advantages that the quality is stable; the disintegration speed is high; the spleen, the lung, the liver and thekidney can be harmonized; the qi is tonified. The invention also provides a preparation method of the herba taxilli tea granule composition.

The invention relates to a formula of mulberry leaf extract tablets. The formula comprises the following components in parts by weight: 40-50 parts of a mulberry leaf extract, 10-15 parts of a fagopyrum tararicum extract, 10-20 parts of a kudzu-vine root extract, 15-20 parts of an astragalus root extract, 6-10 parts of starch, 2-4 parts of xylitol, 2-4 parts of hydroxypropyl methyl cellulose and 1-2 parts of magnesium stearate. The formula overcomes defects of the prior art, on the basis of blood sugar reduction functions of the mulberry leaf extract and the fagopyrum tararicum extract, functions of generating body fluid and quenching thirst and reducing blood sugar, of the kudzu-vine root extract, and functions of enriching qi and reducing blood sugar, of the astragalus root extract, scientific and reasonable compatibility is achieved, and the mulberry leaf extract tablets have good blood sugar reduction functions.

The invention belongs to the medicine field and provides the application of ligustrazine phosphate used for preparing a medicament for curing dilated cardiomyopathy. The ligustrazine phosphate has the following functions of: reducing the death rate of genetic dilated cardiomyopathy, improving the heart function of the dilated cardiomyopathy and relieving the expansion of the left ventricle when the ligustrazine phosphate is used for a long period; relieving the hypertrophy of the myocardial cells of the dilated cardiomyopathy as well as the hyperplasia of interstitial collagen; relieving the uneven thickness of the myocardial fibers, disorderly arrangement, mitochondrial swelling, cristae fragmentation, sarcoplasmic reticulum expansion and damaged intercalated disc connection of the dilated cardiomyopathy; improving the expression of the ligandin Cx40 of the myocardial cells, improving the expression of Myl4 and Myl7 of a myosin light chain, reducing the expression of Myot as well as reducing the expression of collagenous fibers, Col1a1 and Col3a1.

The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition in preparing medicine for treating myocardial apoptosis. The experiments of administrating the medicine composition to spontaneous hypertension rats, measuring the left venticle thickening index, and radioimmunoassay measuring the local Ang II concentration in cardiac muscle and blood plasma and the aldosterone concentration in blood plasma show that the said medicine composition can lower SHR myocardial apoptosis and reduce left venticle thickness when used alone or together with fosinopril.

The invention belongs to the technical field of medicine, in particular relates to a traditional Chinese medicinal composition for treating exogenous evil dry lung type tuberculous pleural effusion. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicine in parts by weight: 4 to 8 parts of old radish root, 4 to 8 parts of cortex syringae, 4 to 8 parts of leaf of pilose combretum, 4 to 8 parts of radix knoxiae, 4 to 8 parts of ginkgo root, 4 to 8 parts of whole herb of aechmanthera tomentosa, 4 to 8 parts of root of ophiuros exaltatus, 4 to 8 parts of golden leaf and 4 to 8 parts of radix glycyrrhizae. The medicine is combined to jointly realize the efficacy of freeing lung-qi and eliminating damp, strengthening the body immunity to eliminate pathogenic factors, and moistening lung and resisting tuberculosis; the traditional Chinese medicinal composition is applied to patients with exogenous evil dry lung type tuberculous pleural effusion, so that pleural effusion can be reduced, pleural thickening, adhesion and wrapping are reduced, the curative effect is improved, and the treatment course is shortened.

The invention discloses a pharmaceutical composition and application thereof, and the pharmaceutical composition is composed of 1, 6-fructose diphosphate (FDP) or a pharmaceutically acceptable salt thereof, and nicotinamide mononucleotide NMN/nicotinamide adenine dinucleotide NAD + or a pharmaceutically acceptable salt thereof. The invention also discloses application of the compound in preparation of medicines for preventing and/or treating primary dysmenorrhea and infertility. The invention discloses an action mechanism of FDP and NMN/NAD < + > combined administration in treating a mouse primary dysmenorrhea model, and finds that the FDP and NMN/NAD < + > combined administration has a better curative effect than FDP or NMN/NAD < + > independent administration, and can obviously reduce the writhing reaction frequency of a female mouse, increase the incubation period of the writhing reaction, reduce the gene expression level of COX-2 and PGF2alpha in uterine tissues, increase the gene expression level of PGE2, and improve the mouse primary dysmenorrhea treatment effect. Infiltration of inflammatory cells is reduced, and uterine tissue edema and inflammatory pathology degree are improved; in addition, combined administration of FDP and NMN/NAD + can significantly increase the pregnancy rate of female mice compared with independent administration of FDP or NMN/NAD +.

The invention belongs to the technical field of medicine, in particular relates to a traditional Chinese medicinal composition for treating fluid retaining chest and hypochondrium type tuberculous pleural effusion. The traditional Chinese medicinal composition is prepared from the following traditional Chinse medicine in parts by weight: 4 to 8 parts of whole herb of lindernia ruellioides, 4 to 8 parts of whole plant of ardisia affinis Hemsl., 4 to 8 parts of leaf of pilose combretum, 4 to 8 parts of radix knoxiae, 4 to 8 parts of flower of rice bean, 4 to 8 parts of fuzhou diospyros root, 4 to 8 parts of root of ophiuros exaltatus, 4 to 8 parts of golden leaf and 4 to 8 parts of radix glycyrrhizae. The medicine is combined to jointly realize the efficacy of regulating Qi and promoting blood circulation, removing retained water and morbid fluid, moistening lung and resisting tuberculosis; the traditional Chinese medicinal composition is applied to patients with fluid retaining chest and hypochondrium type tuberculous pleural effusion, so that pleural effusion can be reduced, pleural thickening, adhesion and wrapping are reduced, the curative effect is improved, and the treatment course is shortened.